Affiliations of authors: Program in Cancer Genetics, Departments of Oncology and Human Genetics, McGill University, Montreal, Quebec, Canada (WDF); Department of Pathology, Gade Institute, Haukeland Hospital, University of Bergen, Norway (LAA).
Correspondence to: William D. Foulkes, MD, PhD, Program in Cancer Genetics, Departments of Oncology and Human Genetics, McGill University, Montreal, Quebec, Canada, H3G 1A4 (e-mail: william.foulkes{at}mcgill.ca)
We note with interest that data from Palacios et al. broadly support our original observation, and that the data from van der Groep et al. extend our findings to include other basal-associated markers, in this case, epidermal growth factor receptor (EGFR). It is notable that van der Groep et al. found that BRCA2-related breast cancers also tended to share the basal epithelioid phenotype previously identified only in BRCA1-related breast cancers. This result should be interpreted cautiously, particularly because only four tumors were studied and because all four BRCA2 tumors were estrogen receptor (ER)-negative, which is unusual. Most BRCA2-related breast cancers are ER-positive (1). Moreover, the reports of Sørlie et al. (2) and Palacios et al. do not suggest that the basal phenotype of BRCA1-related breast cancer is likely to be extendible to BRCA2-related breast cancer.
The data provided by Palacios et al. suggest that the complete ER/erbB2negative, cytokeratin (CK) 5/6-positive phenotype may not be quite so discriminatory of a BRCA1 mutation if age is taken into account. However, in light of our findings and those reported by Palacios et al. and van der Groep et al. we suggest that basal markers, such as CK5/6 and its partner CK14, as well as P-cadherin and EGFR, be evaluated further as first-line immunohistochemical tests for the presence of a germ-line BRCA1 mutation. The finding of van der Groep et al. that the BRCA1-related basal phenotype can be extended to include the basal-associated marker EGFR is consistent with the work of Santini et al. (3), who noted that EGFR expression was frequently observed only in breast cancers with a high nuclear grade that also expressed basal epithelial markers (3). In a more recent study, long-term treatment of basal mammary epithelial cells with EGF resulted in a mobile rather than a stationary phenotype (4), possibly indicating a mechanism by which expression of EGFR influences the behavior of breast cancer cells that possess a basal epithelial phenotype.
One question raised by these observations is whether the basal phenotype of BRCA1-related breast cancer reflects the possible cell of origin of these tumors (5), or instead, the presence of CK5/6 merely represents a particular pattern of differentiation, uncoupled from histogenesis (6). Moreover, whether the CK5/6 intermediate filaments are simply biological bystanders (7) or contributors in their own right to the phenotype of BRCA1-related breast cancer is a key question in determining the true significance of basal cytokeratin staining in hereditary breast cancer.
REFERENCES
1 Chappuis PO, Nethercot V, Foulkes WD. Clinico-pathological characteristics of BRCA1- and BRCA2-related breast cancer. Semin Surg Oncol 2000;18:28795.[CrossRef][ISI][Medline]
2 Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast cancer subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003;100:841823.
3 Santini D, Ceccarelli C, Taffurelli M, Pileri S, Marrano D. Differentiation pathways in primary invasive breast carcinoma as suggested by intermediate filament and biopathological marker expression. J Pathol 1996;179:38691.[CrossRef][ISI][Medline]
4 Deugnier MA, Faraldo MM, Janji B, Rousselle P, Thiery JP, Glukhova MA. EGF controls the in vivo developmental potential of a mammary epithelial cell line possessing progenitor properties. J Cell Biol 2002;159:45363.
5 Foulkes WD. BRCA1 functions as a breast stem cell regulator. J Med Genet 2004;41:15.
6 Gould VE. Histogenesis and differentiation: a re-evaluation of these concepts as criteria for the classification of tumors. Hum Pathol 1986;17:2125[ISI][Medline]
7 Moll R. Cytokeratins as markers of differentiation in the diagnosis of epithelial tumors. Subcell Biochem 1998;31:205262.[Medline]
![]() |
||||
|
Oxford University Press Privacy Policy and Legal Statement |